^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | KT-413 (IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader) |
| Drug Class: | BTK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
013 | KT-413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE-AGENT AND COMBINATION REGRESSIONS IN MYD88MT LYMPHOMA MODELS
Published date:
06/09/2021
Excerpt:
KT-413 also showed strongly additive activity in combination with rituximab or BTK inhibitors in MYD88MT OCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88MT DLBCL.
